AbbVie Inc. $ABBV Shares Sold by Danske Bank A S

Danske Bank A S decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 2.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,284,235 shares of the company’s stock after selling 32,615 shares during the period. AbbVie makes up approximately 0.7% of Danske Bank A S’s portfolio, making the stock its 21st biggest position. Danske Bank A S’s holdings in AbbVie were worth $335,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of ABBV. State Street Corp boosted its position in shares of AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares during the last quarter. Fisher Asset Management LLC increased its position in AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after purchasing an additional 23,991,451 shares during the last quarter. Corient Private Wealth LP acquired a new position in AbbVie during the second quarter worth approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares during the period. Finally, Legal & General Group Plc purchased a new position in AbbVie during the second quarter worth approximately $2,905,952,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Canaccord Genuity Group lifted their target price on AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Piper Sandler increased their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Leerink Partners increased their price objective on shares of AbbVie from $309.00 to $342.00 and gave the stock an “outperform” rating in a research note on Monday, November 2nd. Finally, JPMorgan Chase & Co. lifted their target price on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $297.46.

AbbVie News Summary

Investors following ABBV have been watching these news items:

• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Insiders Place Their Bets

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares in the company, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by insiders.

AbbVie Trading Up 0.2%

NYSE:ABBV traded up $0.73 during mid-day trading on Friday, hitting $295.18. The stock had a trading volume of 3,259,920 shares, compared to its average volume of 5,279,493. The company has a 50 day simple moving average of $275.51 and a 200-day simple moving average of $240.91. The stock has a market capitalization of $521.76 billion, a price-to-earnings ratio of 50.81, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. AbbVie’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.86 earnings per share. As a group, equities research analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a $1.82 dividend. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is 125.30%.

AbbVie Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.